AI trade shifts from hardware to downstream beneficiaries
The guest argued that as the infrastructure and memory bubble peaks, the next phase of the AI trade lies in shorting legacy services and buying downstream beneficiaries like biotech and defense.
The argument
The speaker noted that hyperscalers are building data centers out of competitive survival, which has heavily boosted memory stocks. The next logical trade is identifying what AI will disrupt (e.g., shorting IT consultants like Accenture) and what it will supercharge (e.g., biotech and smart defense drones).
The thesis, stress-tested
✓ What validates it
- ✓Further margin deterioration or revenue declines at major IT consulting firms
- ✓Accelerated FDA approvals or clinical trial successes attributed to AI-driven drug discovery
▸ Risks discussed
- ▸The hardware and memory bubble could persist longer than expected
- ▸Downstream AI integration in biotech and defense may take longer to generate measurable cash flows
Hear it yourself
"And it's because they're genuinely gonna benefit in a massive way from AI. So, you know, maybe short to consultants by biotech defense is obviously, I think, gonna be huge AI is hugely beneficial for defense companies right now as well, because they're building, you know, smart forward deployed drones. It's kind of interesting."
00:00 / 00:21
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE